Gabelli & CO Investment Advisers, Inc. Axonics, Inc. Transaction History
Gabelli & CO Investment Advisers, Inc.
- $535 Million
- Q3 2024
A detailed history of Gabelli & CO Investment Advisers, Inc. transactions in Axonics, Inc. stock. As of the latest transaction made, Gabelli & CO Investment Advisers, Inc. holds 257,293 shares of AXNX stock, worth $18.3 Million. This represents 3.35% of its overall portfolio holdings.
Number of Shares
257,293
Previous 216,150
19.03%
Holding current value
$18.3 Million
Previous $14.5 Million
23.36%
% of portfolio
3.35%
Previous 2.63%
Shares
3 transactions
Others Institutions Holding AXNX
# of Institutions
234Shares Held
42.1MCall Options Held
83.4KPut Options Held
65.3K-
Vanguard Group Inc Valley Forge, PA5.06MShares$359 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.34MShares$308 Million0.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ2.18MShares$155 Million6.99% of portfolio
-
Fil LTD Hamilton, D02.04MShares$145 Million0.14% of portfolio
-
Westchester Capital Management, LLC Valhalla, NY1.45MShares$103 Million4.89% of portfolio
About Axonics, Inc.
- Ticker AXNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 49,123,600
- Market Cap $3.49B
- Description
- Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention...